Amicus Therapeutics Inc (NASDAQ:FOLD)
| 7.33 BATS BZX Real-Time Price As of 9:31am ET |  +0.04 / +0.55%Today’s Change | 5.91 Today|||52-Week Range 12.63 | -36.54% Year-to-Date |
Latest FOLD News | Press Releases
| Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Top Estimates May 10 / Zacks.com - Paid Partner Content | ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates May 06 / Zacks.com - Paid Partner Content |
| Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates May 09 / Zacks.com - Paid Partner Content | Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat May 06 / Zacks.com - Paid Partner Content |
| Aerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/Y May 06 / Zacks.com - Paid Partner Content | Why Amicus (FOLD) Might Surprise This Earnings Season May 06 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 7.29 |
| Today’s open | 7.33 |
| Day’s range | 7.33 - 7.33 |
| Volume | 400 |
| Average volume (3 months) | 3,527,218 |
| Market cap | $2.1B |
Data as of 9:31am ET, 05/19/2022
Growth & Valuation
| Earnings growth (last year) | +13.72% |
| Earnings growth (this year) | +7.04% |
| Earnings growth (next 5 years) | +32.71% |
| Revenue growth (last year) | +17.11% |
| P/E ratio | NM |
| Price/Sales | 10.26 |
| Price/Book | 6.80 |
Competitors
Data as of 4:01pm ET, 05/18/2022
Financials
| Next reporting date | August 10, 2022 |
| EPS forecast (this quarter) | -$0.21 |
| Annual revenue (last year) | $305.5M |
| Annual profit (last year) | -$250.5M |
| Net profit margin | -81.98% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Philadelphia, Pennsylvania |
Forecasts
